Oslo, 29 October 2025 - Reference is made to the previous stock exchange
announcements made in connection with the combination of BerGenBio ASA and
Oncoinvent ASA ("Oncoinvent") through a statutory triangular merger (the
"Merger"), including the announcements made on 4 August 2025 regarding approval
of the Merger by the extraordinary general meetings of the two companies.
Reference is further made to the stock exchange announcement made on 24 October
2025 regarding key dates for completion of the Merger and the stock exchange
announcement made on 28 October 2025 regarding the approval and publication of
the prospectus (the "Prospectus") prepared in connection with the Merger and the
contemplated rights issue in the combined company.

Completion of the Merger has today been registered with the Norwegian Register
of Business Enterprises. Consequently, Oncoinvent has been dissolved and the
name of BerGenBio ASA has been changed to Oncoinvent ASA (the "Combined
Company"). Following the issuance of the 117,554,012 merger consideration shares
(the "Merger Shares") to be delivered to former shareholders of Oncoinvent, the
new share capital of the Combined Company is NOK 156,641,128, divided into
156,641,128 shares, each with a nominal value of NOK 1.

The Merger Shares will be distributed on a pro rata basis to the former
shareholders of Oncoinvent as of 29 October 2025 (as registered in Euronext
Securities Oslo on 31 October 2025), and are expected to be delivered in
Euronext Securities Oslo on or about 3 November 2025.

For further details on the Merger, please see the announcements mentioned above
and the Prospectus.

The Combined Company will give an update on the Merger as well as a quarterly
update in a live virtual presentation on 4 November 2025 at 08:30 (CET). The
presentation will be broadcasted live on
https://channel.royalcast.com/landingpage/hegnarmedia/20251104_9/. The Combined
Company will give a status on the ongoing phase 2 ovarian cancer study including
a status on recruitment of 20 patients by the end of the third quarter of 2025,
as well as a financial status.

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.
About Oncoinvent ASA
Oncoinvent ASA is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent ASA is investigating the safety and efficacy of Radspherin® in a
clinical development program in two indications. One Phase 1 trial and one Phase
1/2a trial have been completed and one randomized Phase 2 trial is currently
ongoing in the US, UK and Europe. Early clinical efficacy data are highly
encouraging, and no serious toxicity or safety concerns have been reported to
date. The Oncoinvent ASA team consists of approx. 40 employees and runs a state
-of-the-art manufacturing facility to produce drug products for clinical trials
in Nydalen, Oslo. Oncoinvent ASA is listed on the Euronext Oslo Børs.
Forward-looking statement:
All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that the
Combined Company's plans, estimates, or expectations will be achieved. These
forward-looking statements represent the Combined Company's expectations as of
the date of this press release, and the Combined Company disclaims any
obligation to update the forward-looking statements. These forward-looking
statements are subject to known and unknown risks and uncertainties that may
cause actual results to differ materially, including with respect to whether the
results of clinical or other studies will support the use of our product
offerings, the impact of results of such studies, our expectations of the
reliability, accuracy and performance of our tests, or of the benefits of our
tests and product offerings to patients, providers and payers.